CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project explores the use of low-temperature plasma to treat cancer by generating reactive oxygen species that stimulate immune responses. It aims to optimize cancer treatment by using plasma-treated cancer lysates as a therapeutic vaccine, enhancing the body's ability to recognize and eliminate tumor cells.
Efficient anticancer immune effects are a prime medical discovery of this century.
Molecular alarms drive such immune responses, signaling priming and effector cells to action.
Several approaches are studied or clinically used to initiate or support such action.
Yet, the perhaps evolutionary old and most conserved mechanism has been mostly off the map so far: reactive oxygen species (Physical-technical applications extend into medicine for diagnostics and also therapies, such as: cancer treatmen…
LEIBNIZ-INSTITUT FUR PLASMAFORSCHUNG UND TECHNOLOGIE EV
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
